Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients - Full Text View

Sponsor:	Topigen Pharmaceuticals
Information provided by:	Topigen Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00483743

Purpose

This study will assess and compare the safety and tolerability of inhaled TPI 1020 (repeated nominal doses; 500 μg BID x 6 weeks) versus inhaled budesonide (repeated doses; 800 μg BID x 6 weeks) and a matching placebo. Pharmacodynamic (PD) activity on FEV1, sputum and blood cells and cytokines will also be studied.

Condition	Intervention	Phase
COPD Patients	Drug: TPI 1020 Drug: Budesonide Drug: Placebo	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Official Title:	Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled, 6-Week Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI 1020 in COPD Patients.

Resource links provided by NLM:

Drug Information available for: Budesonide

U.S. FDA Resources

Further study details as provided by Topigen Pharmaceuticals:

Primary Outcome Measures:

To determine the airway specific, and general safety and the tolerability of inhaled TPI 1020 administered via Aerolizer™ in COPD patients. • To assess the effects of TPI 1020 versus those of budesonide on sputum neutrophil counts on Days 0 and 42. [ Time Frame: 42 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Sputum neutrophil counts on Days 0 and 21. • Trough FEV1, SVC and IC on Days 0, 21 and on Day 42. • eNO levels on Days 0, 21 and on Day 42. [ Time Frame: 42 days ] [ Designated as safety issue: No ]

Enrollment:	62
Study Start Date:	November 2007
Study Completion Date:	December 2008
Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental TPI 1020 500 mcg BID x 42 days	Drug: TPI 1020 250 mcg/caps 2 caps BID x 42 days
2: Active Comparator Budesonide 800 mcg BID x 42 days	Drug: Budesonide 400mcg mcg capsules- 2 capsules BID
3: Placebo Comparator	Drug: Placebo 2 caps BID x42 days

Detailed Description:

A multi-centre, randomized, placebo and active-controlled, 6-week study of inhaled TPI 1020, inhaled budesonide or matching placebo (random allocation of eligible patients to the three treatments at a ratio of 3:3:1), to evaluate the safety, tolerability and pharmacodynamic activity of TPI 1020 in 42 evaluable COPD subjects.

Eligibility

Ages Eligible for Study:	40 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Outpatients, male or female, smoker or ex-smoker (who quit at least a year ago) with a smoking history equal or greater than 10 pack years.
Age between 40 and 80 years old with a diagnosis (for at least 12 months) of mild to moderate COPD

Exclusion Criteria:

COPD exacerbations indicated by a treatment with oral or systemic glucocorticosteroids and/or hospitalization and/or clinically relevant respiratory infection requiring antibiotics within 3 month of the start of the study.
Failure to produce a sufficient sputum sample during the screening sputum induction procedure, required for TCC and differential cell count determination.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00483743

Locations

Canada, Alberta
University of alberta Hsopital
Edmonton, Alberta, Canada, T6G2B7
Canada, British Columbia
Vancouver Hospital Lung Center
Vancouver, British Columbia, Canada, V5Z 1 M9
Canada, Ontario
Firestone Institute for Respiratory Health
Hamilton, Ontario, Canada, L8N4A6
Canada, Quebec
CHUS -Hopital FLEURIMONT
Sherbrooke, Quebec, Canada, J1H5N4
Hopital Thoracique Montreal-CSUM
Montreal, Quebec, Canada, H2X2P4
Centre de Cardiologie et de Pneumologie de l'Université Laval
Ste-Foy, Quebec, Canada, G1V 4G5
Complexe Medicale Langelier
St-Leonard, Quebec, Canada, H1S 3A9
Hopital Sacre Coeur de Montreal
Montreal, Quebec, Canada, H4J1C5
Omnispec Clinical Research Inc.
Mirabel, Quebec, Canada, J7J 2K8
Clinique Medical Les Saules
Les Saules, Quebec, Canada, G1P 1J6
Diex Research Inc.
Sherbrooke, Quebec, Canada, J1H 1Z1
Kells Medical Research Group
Pointe-Claire, Quebec, Canada, H9R 4S3
Canada, Saskatchewan
Royal University Hospital
Saskatoon, Saskatchewan, Canada, S7N 0W8

Sponsors and Collaborators

Topigen Pharmaceuticals

Investigators

Principal Investigator:	Francois Maltais, MD	Centre de Cardiologie et de Pneumologie de l'Université Laval
Study Director:	Rene Pageau, M.Sc Pharm	Topigen Pharmaceuticals

More Information

No publications provided

Responsible Party:	Topigen Pharmaceuticals Inc. ( Rene Pageau, Sr Director Clinical Research )
Study ID Numbers:	TPI 1020-203
Study First Received:	May 23, 2007
Last Updated:	March 4, 2009
ClinicalTrials.gov Identifier:	NCT00483743 History of Changes
Health Authority:	Canada: Health Canada

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Respiratory System Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Budesonide
Anti-Asthmatic Agents
Hormones
Glucocorticoids
Pharmacologic Actions

Lung Diseases, Obstructive
Respiratory Tract Diseases
Autonomic Agents
Lung Diseases
Therapeutic Uses
Peripheral Nervous System Agents
Bronchodilator Agents
Pulmonary Disease, Chronic Obstructive

ClinicalTrials.gov processed this record on February 08, 2010